image 2 image 4
Skip Navigation Links
 Home 
 Congress Structure 
 Important Dates 
 Venue 
 Registration 
 Pre Registered 
 Abstracts 
 Scientific Program 
 Photo and Film Festival 
 Exhibition 
 Contact Us 
 Personal page 
       XXVIII Annual Congress of the Iranian Society of Ophthalmology        بـیــست و هشتمین کنــگــره سـالیـانه انـجـمـن چـشـم پـزشـکی ایـــران
مقاله Abstract


Title: Efficacy of Adjuvant Topical Timolol-Dorzolamide with Intravitreal Bevacizumab Injection in Diabetic Macular Edema: Contralateral Eye Study
Author(s): Ahmad Mirshahi MD; Ramin Tadayoni MD ; Navid Mohsenzadeh MD; Talieh Saeidi Rezvani MSc; Mojtaba Abrishami MD
Presentation Type: Oral
Subject: Posterior Segment
Others:
Presenting Author:
Name: Mojtaba Abrishami
Affiliation :(optional) Eye Research Center, Khatam Eye Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
E mail: mojtaba_abrishami@yahoo.com
Phone: 05138433192
Mobile: 09129377278
Purpose:

To evaluate the efficacy of adjuvant topical Timolol-Dorzolamide with intravitreal bevacizumab (IVB) injection on anatomic and functional outcomes in eyes with diabetic macular edema (DME).

Methods:

In a prospective contralateral eye, interventional pilot study at a tertiary referral academic center, patients with bilateral DME who were treatment naive were enrolled. Enrolled patients received a regimen of topical dorzolamide-timolol twice daily in the right eye and three bilateral monthly IVB injection 1.25mg/ 0.05ml were planned. Baseline central macular thickness (CMT) measured by spectral-domain optical coherence tomography and clinical data, including best corrected visual acuity (BCVA) and intraocular pressure (IOP) , were obtained at enrollment and one month after the third injection.

Results:

Eleven patients (seven female) with DME were included. BCVA and CMT were improved in both eyes and IOP was decreased in the right eye but was not changed in the left eye. In repeated measures ANOVA analysis, decrease in CMT and improvement in BCVA was significant in the right eye.

Conclusion:

Data of our study suggest that adjuvant topical dorzolamide-timolol in combination with IVB may be further reducing central macular thickness in eyes with DME.

Attachment:





Skip Navigation Links
        صفحه اصلی
        ساختار کنگره
        تاریخ های مهم
        مکان برگزاری
        ثبت نام
        ثبت نام شدگان
        اطلاعات هتل - رزرو
        مقالات
        برنامه کنگره
        جشنواره فیلم و عکس
        نمایشگاه
        تماس با ما
        صفحه شخصی
        جستجوی سخنران
        آرشیو کنگره سالهای گذشته
        شب کنگره چشم پزشکی
 
ورود شرکت کنندگان
نام کاربری :
کلمه عبور :
  کلمه عبور خود را فراموش کرده ام.
Total Visits
Find us on Social Media
Congress Count Down
Today Label
Last Month Label
Total Visitors Label